Delcath seeks approval of chemosaturation system

Delcath Systems Inc. (NASDAQ:DCTH) submitted an NDA to FDA for its chemosaturation system delivering melphalan to treat unresectable metastatic melanoma in the liver. The company, which requested Prio...